STAT Plus: Biogen execs have been quiet since Covid-19 spread through the biotech. The silence ends Wednesday
Do they go with a Covid-19 question? Or one about aducanumab? Maybe a combination of both.
One of biotech’s sell-side analysts — perhaps Geoff Porges from SVB Leerink, or J.P. Morgan’s Cory Kasimov, or Umer Raffat of Evercore ISI — will ask the first question of Biogen (BIIB) chief executive Michel Vounatsos when its first-quarter earnings call kicks off on Wednesday morning.
